Source:http://linkedlifedata.com/resource/pubmed/id/18467141
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2008-6-16
|
| pubmed:abstractText |
The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma 2 gene is suggested to associate with diabetic nephropathy and cardiovascular disease in type 2 diabetes. The aim of this study was to investigate the polymorphism in relation to diabetic nephropathy, end-stage renal disease (ESRD), mortality and cardiovascular (CVD) events in type 1 diabetic patients. This prospective observational follow-up study included 415 type 1 diabetic patients with overt diabetic nephropathy (252 men; age 42.2+/-10.4 years [mean+/-SD], duration of diabetes 28.3+/-8.8 years, GFR 66+/-8.8 ml/min) and 428 patients with longstanding type 1 diabetes and persistent normoalbuminuria (230 men; age 45.4+/-11.6 years, duration of diabetes 27.8+/-10.1 years). Follow-up: 8.1 (0.0-12.8) years (median [range]). There where no significant differences between cases and controls in genotype (p=0.51) or allele frequencies (p=0.25). Cox regression analysis revealed a covariate-adjusted hazard ratio (HR) for all-cause mortality in patients with the Ala/Ala genotype of 2.44 (1.23-4.84). The Pro12Ala polymorphism did not predict CVD events. However, the Ala/Ala genotype predicts ESRD (covariate-adjusted HR 2.60 (1.11-6.07)). Furthermore, Carriers of the Ala-allele had a higher rate of decline in GFR (p=0.040). In conclusion, the Pro12Ala polymorphism is not associated with type 1 diabetic nephropathy. The Ala-allele is associated with enhanced decline in GFR and predicts ESRD and all-cause mortality in patients with nephropathy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
1096-7206
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
94
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
347-51
|
| pubmed:meshHeading |
pubmed-meshheading:18467141-Adult,
pubmed-meshheading:18467141-Case-Control Studies,
pubmed-meshheading:18467141-Diabetes Mellitus, Type 1,
pubmed-meshheading:18467141-Diabetic Nephropathies,
pubmed-meshheading:18467141-Female,
pubmed-meshheading:18467141-Follow-Up Studies,
pubmed-meshheading:18467141-Gene Frequency,
pubmed-meshheading:18467141-Genetic Predisposition to Disease,
pubmed-meshheading:18467141-Glomerular Filtration Rate,
pubmed-meshheading:18467141-Humans,
pubmed-meshheading:18467141-Kidney Failure, Chronic,
pubmed-meshheading:18467141-Male,
pubmed-meshheading:18467141-Middle Aged,
pubmed-meshheading:18467141-PPAR gamma,
pubmed-meshheading:18467141-Polymorphism, Single Nucleotide,
pubmed-meshheading:18467141-Prognosis,
pubmed-meshheading:18467141-Prospective Studies,
pubmed-meshheading:18467141-Survival Analysis
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
The PPAR gamma 2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy.
|
| pubmed:affiliation |
Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark. ajrs@steno.dk
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|